dr. tyna moore glp-1 She Started the Microdosing Trend — Here's What She's Saying Now Using GLP-1s: Benefits, Beyond Obesity

This discouraged researchers from pursuing GIP as a therapeutic target

Hepatic Lipid Metabolism Research The glucagon-receptor component of retatrutide drives interest in hepatic lipid handling

However, the results may signal that as GLP-1 use becomes more widespread, preferences could gradually shift away from highly energy-dense and ultra-processed products towards foods with lower energy density and higher protein content

This finding is biologically plausible

No medical advice

The administration of pharmacologic quantities of GLP-1 analogs result in plasma activities that are 5- to 7-fold higher than physiologic levels